ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Pitt Inquiry Panel Proceedings Suspended, ORI To Take Over NSABP Investigation

July 22, 1994

Phase II Study Of Pfizer Drug Meets Primary Endpoint

April 24, 2009

Human Genome Project publishes its final product.

October 22, 2004

Amgen Announces Cochrane Findings: ESAs Increase Risk Of On-Study Death.

October 3, 2008

FDA’s Kweder cites Society of Professional Journalists’ Code of Ethics–incorrectly, SPJ says.

March 4, 2005

Van Potter Wins Bristol-Myers Award

April 24, 1981